With increased safety concerns surrounding the long-term use of bisphosphonates, 30, 36, 85 questions have arisen regarding the applicability of “drug holidays” to minimize long-term bisphosphonate exposure and avoid potential adverse events while maintaining some degree of antifracture efficacy through the residual antiresorptive activity of retained bisphosphonate.
Due to the long half-life of bisphosphonates, the persistence of the anti-resorptive effects is expected for an undefined period of time. Your opinions are important to us.
Your email address is used Ongoing treatment with bisphosphonate therapy may not be needed to prevent future fractures in certain patients due to the sustained effect of the drug. Longer Bisphosphonate Drug Holiday May Up Fracture Risk. National guidance is not available on whether a drug holiday is required, which patients would be suitable or for how long the holiday should be. Int., 30 (2019), pp. Bisphosphonates have been shown to reduce the risk of osteoporotic fractures.
Epub 2019 Jan 8.Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF).Osteoporos Int.
Name must be less than 100 characters
The suggestion of stopping therapy or a drug ‘holiday’ after 5 years treatment has been made in the literature. Epub 2015 Sep 11.Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollieres FA, Goulis DG.Maturitas. Ultimately, while an interruption in therapy may be appropriate for some patients, it is important for the clinician to reiterate to the patient that the drug may need to be restarted in the future, as the effects on the bone may diminish over time. 2019 Apr;30(4):705-720. doi: 10.1007/s00198-018-4791-3. 2019 Apr;30(4):705-720. doi: 10.1007/s00198-018-4791-3. The analysis included the observations of 1,973 participants who had been recruited from physicians' practices and clinics throughout Germany.In a simple two-group comparison, the research team found no difference in fracture risk between patients whose The analyses suggest that longer drug holidays from bisphosphonates are associated with an at least partial loss of their protective effect against fractures. Clinicians must be prepared to have this discussion, especially considering the potentially significant, although rare, adverse effects of bisphosphonate therapy. Phys.org internet news portal provides the latest news on scienceTech Xplore covers the latest engineering, electronics and technology advances Science X Network offers the most comprehensive sci-tech news coverage on the web 2017 Jul;101:23-30. doi: 10.1016/j.maturitas.2017.04.008. Unable to load your collection due to an error In addition, treatment breaks reduce the risk for adverse events from the drug. 2019 Sep;30(9):1733-1743. doi: 10.1007/s00198-019-05002-w. Epub 2019 Jun 7.Salgueiro M, Stribos M, Zhang LF, Stevens M, Awad ME, Elsalanty M.EPMA J. Patients should be monitored for fracture during a treatment break, along with evaluation of BMD every 2 to 3 years. Springer
Epub 2017 Nov 27.Osteoporos Int. 2019 Jan 24;10(1):21-29. doi: 10.1007/s13167-019-0160-3.
The risk of new clinical fractures was found to be 40% higher in women who had taken a BP "drug holiday."
The research team published its findings in the journal Long-term treatment with bisphosphonates is associated with an increase in rare, albeit serious side effects, especially osteonecrosis of the jaw or certain fractures of the thigh. S. Nayak, S.L. 2018 Feb;29(2):521. doi: 10.1007/s00198-017-4320-9.
With increased safety concerns surrounding the long-term use of bisphosphonates, 30, 36, 85 questions have arisen regarding the applicability of “drug holidays” to minimize long-term bisphosphonate exposure and avoid potential adverse events while maintaining some degree of antifracture efficacy through the residual antiresorptive activity of retained bisphosphonate.
Due to the long half-life of bisphosphonates, the persistence of the anti-resorptive effects is expected for an undefined period of time. Your opinions are important to us.
Your email address is used Ongoing treatment with bisphosphonate therapy may not be needed to prevent future fractures in certain patients due to the sustained effect of the drug. Longer Bisphosphonate Drug Holiday May Up Fracture Risk. National guidance is not available on whether a drug holiday is required, which patients would be suitable or for how long the holiday should be. Int., 30 (2019), pp. Bisphosphonates have been shown to reduce the risk of osteoporotic fractures.
Epub 2019 Jan 8.Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF).Osteoporos Int.
Name must be less than 100 characters
The suggestion of stopping therapy or a drug ‘holiday’ after 5 years treatment has been made in the literature. Epub 2015 Sep 11.Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollieres FA, Goulis DG.Maturitas. Ultimately, while an interruption in therapy may be appropriate for some patients, it is important for the clinician to reiterate to the patient that the drug may need to be restarted in the future, as the effects on the bone may diminish over time. 2019 Apr;30(4):705-720. doi: 10.1007/s00198-018-4791-3. 2019 Apr;30(4):705-720. doi: 10.1007/s00198-018-4791-3. The analysis included the observations of 1,973 participants who had been recruited from physicians' practices and clinics throughout Germany.In a simple two-group comparison, the research team found no difference in fracture risk between patients whose The analyses suggest that longer drug holidays from bisphosphonates are associated with an at least partial loss of their protective effect against fractures. Clinicians must be prepared to have this discussion, especially considering the potentially significant, although rare, adverse effects of bisphosphonate therapy. Phys.org internet news portal provides the latest news on scienceTech Xplore covers the latest engineering, electronics and technology advances Science X Network offers the most comprehensive sci-tech news coverage on the web 2017 Jul;101:23-30. doi: 10.1016/j.maturitas.2017.04.008. Unable to load your collection due to an error In addition, treatment breaks reduce the risk for adverse events from the drug. 2019 Sep;30(9):1733-1743. doi: 10.1007/s00198-019-05002-w. Epub 2019 Jun 7.Salgueiro M, Stribos M, Zhang LF, Stevens M, Awad ME, Elsalanty M.EPMA J. Patients should be monitored for fracture during a treatment break, along with evaluation of BMD every 2 to 3 years. Springer
Epub 2017 Nov 27.Osteoporos Int. 2019 Jan 24;10(1):21-29. doi: 10.1007/s13167-019-0160-3.
The risk of new clinical fractures was found to be 40% higher in women who had taken a BP "drug holiday."
The research team published its findings in the journal Long-term treatment with bisphosphonates is associated with an increase in rare, albeit serious side effects, especially osteonecrosis of the jaw or certain fractures of the thigh. S. Nayak, S.L. 2018 Feb;29(2):521. doi: 10.1007/s00198-017-4320-9.
With increased safety concerns surrounding the long-term use of bisphosphonates, 30, 36, 85 questions have arisen regarding the applicability of “drug holidays” to minimize long-term bisphosphonate exposure and avoid potential adverse events while maintaining some degree of antifracture efficacy through the residual antiresorptive activity of retained bisphosphonate.
Due to the long half-life of bisphosphonates, the persistence of the anti-resorptive effects is expected for an undefined period of time. Your opinions are important to us.
Your email address is used Ongoing treatment with bisphosphonate therapy may not be needed to prevent future fractures in certain patients due to the sustained effect of the drug. Longer Bisphosphonate Drug Holiday May Up Fracture Risk. National guidance is not available on whether a drug holiday is required, which patients would be suitable or for how long the holiday should be. Int., 30 (2019), pp. Bisphosphonates have been shown to reduce the risk of osteoporotic fractures.
Epub 2019 Jan 8.Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF).Osteoporos Int.
Name must be less than 100 characters
The suggestion of stopping therapy or a drug ‘holiday’ after 5 years treatment has been made in the literature. Epub 2015 Sep 11.Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollieres FA, Goulis DG.Maturitas. Ultimately, while an interruption in therapy may be appropriate for some patients, it is important for the clinician to reiterate to the patient that the drug may need to be restarted in the future, as the effects on the bone may diminish over time. 2019 Apr;30(4):705-720. doi: 10.1007/s00198-018-4791-3. 2019 Apr;30(4):705-720. doi: 10.1007/s00198-018-4791-3. The analysis included the observations of 1,973 participants who had been recruited from physicians' practices and clinics throughout Germany.In a simple two-group comparison, the research team found no difference in fracture risk between patients whose The analyses suggest that longer drug holidays from bisphosphonates are associated with an at least partial loss of their protective effect against fractures. Clinicians must be prepared to have this discussion, especially considering the potentially significant, although rare, adverse effects of bisphosphonate therapy. Phys.org internet news portal provides the latest news on scienceTech Xplore covers the latest engineering, electronics and technology advances Science X Network offers the most comprehensive sci-tech news coverage on the web 2017 Jul;101:23-30. doi: 10.1016/j.maturitas.2017.04.008. Unable to load your collection due to an error In addition, treatment breaks reduce the risk for adverse events from the drug. 2019 Sep;30(9):1733-1743. doi: 10.1007/s00198-019-05002-w. Epub 2019 Jun 7.Salgueiro M, Stribos M, Zhang LF, Stevens M, Awad ME, Elsalanty M.EPMA J. Patients should be monitored for fracture during a treatment break, along with evaluation of BMD every 2 to 3 years. Springer
Epub 2017 Nov 27.Osteoporos Int. 2019 Jan 24;10(1):21-29. doi: 10.1007/s13167-019-0160-3.
The risk of new clinical fractures was found to be 40% higher in women who had taken a BP "drug holiday."
The research team published its findings in the journal Long-term treatment with bisphosphonates is associated with an increase in rare, albeit serious side effects, especially osteonecrosis of the jaw or certain fractures of the thigh. S. Nayak, S.L. 2018 Feb;29(2):521. doi: 10.1007/s00198-017-4320-9.
Apart from any fair dealing for the purpose of private study or research, no Registration is free.- Clinical News, with personalized daily picks for youPlease login or register first to view this content. "However, the number of studies that have investigated the risks and benefits of In order to obtain additional information, the research team interviewed patients who had been treated with these drugs in the preceding four or more years. Although a “drug holiday” from bisphosphonate therapy is not justified in certain patients, such as those who remain at high risk for spine fracture, it may be reasonable for patients who are not at high risk, according to some experts.
With increased safety concerns surrounding the long-term use of bisphosphonates, 30, 36, 85 questions have arisen regarding the applicability of “drug holidays” to minimize long-term bisphosphonate exposure and avoid potential adverse events while maintaining some degree of antifracture efficacy through the residual antiresorptive activity of retained bisphosphonate.
Due to the long half-life of bisphosphonates, the persistence of the anti-resorptive effects is expected for an undefined period of time. Your opinions are important to us.
Your email address is used Ongoing treatment with bisphosphonate therapy may not be needed to prevent future fractures in certain patients due to the sustained effect of the drug. Longer Bisphosphonate Drug Holiday May Up Fracture Risk. National guidance is not available on whether a drug holiday is required, which patients would be suitable or for how long the holiday should be. Int., 30 (2019), pp. Bisphosphonates have been shown to reduce the risk of osteoporotic fractures.
Epub 2019 Jan 8.Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF).Osteoporos Int.
Name must be less than 100 characters
The suggestion of stopping therapy or a drug ‘holiday’ after 5 years treatment has been made in the literature. Epub 2015 Sep 11.Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollieres FA, Goulis DG.Maturitas. Ultimately, while an interruption in therapy may be appropriate for some patients, it is important for the clinician to reiterate to the patient that the drug may need to be restarted in the future, as the effects on the bone may diminish over time. 2019 Apr;30(4):705-720. doi: 10.1007/s00198-018-4791-3. 2019 Apr;30(4):705-720. doi: 10.1007/s00198-018-4791-3. The analysis included the observations of 1,973 participants who had been recruited from physicians' practices and clinics throughout Germany.In a simple two-group comparison, the research team found no difference in fracture risk between patients whose The analyses suggest that longer drug holidays from bisphosphonates are associated with an at least partial loss of their protective effect against fractures. Clinicians must be prepared to have this discussion, especially considering the potentially significant, although rare, adverse effects of bisphosphonate therapy. Phys.org internet news portal provides the latest news on scienceTech Xplore covers the latest engineering, electronics and technology advances Science X Network offers the most comprehensive sci-tech news coverage on the web 2017 Jul;101:23-30. doi: 10.1016/j.maturitas.2017.04.008. Unable to load your collection due to an error In addition, treatment breaks reduce the risk for adverse events from the drug. 2019 Sep;30(9):1733-1743. doi: 10.1007/s00198-019-05002-w. Epub 2019 Jun 7.Salgueiro M, Stribos M, Zhang LF, Stevens M, Awad ME, Elsalanty M.EPMA J. Patients should be monitored for fracture during a treatment break, along with evaluation of BMD every 2 to 3 years. Springer
Epub 2017 Nov 27.Osteoporos Int. 2019 Jan 24;10(1):21-29. doi: 10.1007/s13167-019-0160-3.
The risk of new clinical fractures was found to be 40% higher in women who had taken a BP "drug holiday."
The research team published its findings in the journal Long-term treatment with bisphosphonates is associated with an increase in rare, albeit serious side effects, especially osteonecrosis of the jaw or certain fractures of the thigh. S. Nayak, S.L. 2018 Feb;29(2):521. doi: 10.1007/s00198-017-4320-9.
Got something to say?